RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has released its annual letter to shareholders. The 2017 letter is focused on updating shareholders on the Company's product development and commercial partnerships, anticipated clinical milestones, fund-raising, and other operational plans over the next twelve months. To view the letter, please go to www.regenerx.com or click on the following link: http://www.regenerx.com/image/LettertoShareholders2017.pdf.
